When it comes to the pandemic, the U.S. isn’t out of the woods just yet. For one, demand for testing devices could outstrip supply for a long time, as noted by Roche Chief Executive Severin Schwan, as noted by Reuters. “We still have little information about duration and efficacy of vaccines. So diagnostics will remain very important, not only for the months to come but the years to come.” Two, labs across the country can’t get their hands on enough necessary supply, says CNBC, which added, “The surge in demand is yet again stressing the supply chain for PCR molecular tests — the gold standard in CV-19 testing — leading to long lines for testing, shortages in testing supplies and processing delays across the country.” With the situation growing worse, some companies to keep an eye on include Datametrex AI Ltd. (TSXV:DM)(OTC:DTMXF), Air Canada (TSX:AC)(OTC:ACDVF), Laboratory Corp. of America Holdings (NYSE:LH), Abbott Laboratories (NYSE:ABT), and Quest Diagnostics Inc. (NYSE:DGX).
Datametrex AI Limited (TSXV:DM)(OTC:DTMXF) BREAKING NEWS: Datametrex AI Limited wishes to provide clarity on a statement that was published on Twitter by Air Canada regarding CV-19 testing and Datametrex on November 22, 2020.
The official Air Canada Twitter channel @AirCanada replied to a tweet on a question posted regarding CV-19 trusted testing partners for travel to the state of Hawaii. Air Canada provided the following reply, “The state of Hawaii will only accept CV-19 PCR - Nucleic Acid Amplification Test (NAAT) from a certified Clinical Laboratory from trusted testing and travel partners. In Canada those are: LIFE LABS, DYNACARE, Datametrex al limited, Biron, and DynaLIFE MEDICAL LABS. /Ariana.”
Though the Company has not commented on the tweet publicly, several inquiries on the tweet have been put to management. What the Company can confirm is that Datametrex is completing an agreement to support Canadian communities and provide pre-departure coronavirus (CV-19) PCR-based testing for travelers in several large metropolitan centers within Canada. These tests will be available for travelers flying to any destination requiring a negative CV-19 test.
As a trusted testing and travel partner, Datametrex will provide further commentary in a news release on locations and specifics to the CV-19 testing for travelers. Datametrex believes that testing and peace of mind are important to your health and wellness.
Important CV-19 Considerations
Note: Health Canada does not advise you to get a CV-19 test if you do not have symptoms of the virus. Since a negative result is required for the Hawaiian pre-testing program, this would go against public health advice.
The Government of Canada also warns against travel outside of the country. Due to the CV-19 pandemic, governments that have opened their borders to tourists could impose strict travel restrictions suddenly, which could make it difficult for you to return home.
Under measures from provincial Governments in Canada, all arriving passengers from outside of Canada, regardless of their final destination, are required to submit a self-isolation plan. It must show that returning passengers have supports in place to safely self-isolate for 14 days.
Other related developments from around the markets include:
Air Canada (TSX:AC)(OTC:ACDVF) said it is the first Canadian airline to offer its customers the safety and convenience of a new boarding option utilizing facial biometrics. The technology is now available for customers departing San Francisco International Airport (SFO) with plans to progressively roll it out for customers at other US airports where the airline operates. "Air Canada has introduced numerous touchless processes throughout the customer journey, and we are pleased to now offer an optional, innovative biometric boarding choice for customers departing SFO that is seamless, time-saving and convenient while reducing contact and processing time," said Andrew Yiu, Vice President, Product at Air Canada.
Laboratory Corp. of America Holdings (NYSE:LH) a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for the Pixel by LabCorp™ CV-19 Test Home Collection Kit to become the first to be available over the counter without requiring a prescription. The kit is currently available through the Pixel by LabCorp website and this approval will enable LabCorp to potentially distribute the kit through retail channels. This authorization is the latest example of LabCorp’s commitment to increase access to CV-19 testing. The kit allows consumers to self-collect their sample in the privacy of their own home, which helps minimize transmission of the virus. Users then send the sample for processing at LabCorp .
Abbott Laboratories (NYSE:ABT) announced the global release of its first virtual reality-based training program designed to change how interventional cardiologists are trained in using optical coherence tomography (OCT) imaging technology. The comprehensive new training program incorporates virtual reality (VR) with traditional training techniques to increase experience and expertise in using Abbott’s OCT imaging and improve outcomes in patients needing a stent to open clogged arteries. Abbott is expanding its training portfolio to help physicians gain experience with new therapy options, imaging and diagnostic tools to help improve patient outcomes. Virtual reality presents a promising approach to OCT training because it enables physicians to have the full experience of being in the catheterization laboratory by putting them in the "driver’s seat" with imaging technology.
Quest Diagnostics Inc. (NYSE:DGX) Health Trends study finds that three in four Americans who believed they needed a CV-19 test (74%) chose not to get one, or delayed getting one, primarily due to concerns about exposure to the SARS-CoV-2 virus (30%). The nationally representative survey was conducted online by The Harris Poll on behalf of Quest Diagnostics (NYSE: DGX) between November 10-12, 2020, among 2,050 U.S. adults. This survey is believed to be the first to evaluate attitudes about CV-19's impact on medical care and testing since the recent fall-winter wave of CV-19 cases began to sweep across the United States. The findings suggest large numbers of Americans are putting off medical care they may need – including CV-19 diagnostic lab tests as well as preventative and chronic care – due to fears and other barriers, with likely long-term consequences for patients and the U.S. healthcare system.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Datametrex AI Limited by a third party. We own ZERO shares of Datametrex AI Limited. Please click here for full disclaimer.
Contact Information:
2818047972
[email protected]
